Canaccord analyst Whitney Ijem lowered the firm’s price target on Palvella Therapeutics (PVLA) to $52 from $53 and keeps a Buy rating on the shares. The firm said its 1Q25 earnings report was incrementally positive relative to our recent initiation. Pipeline progress remains on track, and newly announced was that QTORIN rapamycin’s Ph3 had exceeded the target enrollment goal of n=40 ahead of schedule.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Promising Outlook for Palvella Therapeutics: Buy Rating Backed by Strong Financials and Innovative QTORIN Platform
- Palvella Therapeutics Reports Strong Q1 Financial Results
- Palvella Therapeutics reports Q1 EPS (74c), consensus ($1.32)
- Palvella Therapeutics expects cash to fund operations into H2 of 2027
- Promising Potential of QTORIN in Addressing Unmet Needs in Vascular Anomalies: A Buy Recommendation for Palvella Therapeutics